{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:52:49Z","timestamp":1795211569939,"version":"4.10.3"},"reference-count":182,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in understanding the ways in which the immune system fails to control tumor\u00a0growth or prevent autoimmunity have led to the development of powerful therapeutic strategies to treat these diseases. In contrast to conventional therapies that have a broadly suppressive effect, immunotherapies are more akin to targeted therapies because they are mechanistically driven and are typically developed with the goal of \u201cdrugging\u201d a specific underlying pathway or phenotype. This means that their effects and toxicities are, at least in theory, more straightforward to anticipate. The development of functionalized antibodies, genetically engineered T cells, and immune\u00a0checkpoint inhibitors continues to accelerate, illuminating new biology and bringing new treatment to patients. In the following sections, we provide an overview of\u00a0immunotherapeutic concepts, highlight recent advances in the field of immunotherapies, and discuss controversies and future directions, particularly as these pertain to hematologic oncology or blood-related diseases. We conclude by illustrating how original research published in this journal fits into and contributes to the overall framework of advances in immunotherapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004453c","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T19:23:34Z","timestamp":1632857014000},"page":"3709-3725","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["The promise and perils of immunotherapy"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-7666","authenticated-orcid":false,"given":"Stefanie","family":"Lesch","sequence":"first","affiliation":[{"name":"1Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA; and"},{"name":"2Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA; and"},{"name":"2Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"2022061013320856100_B1","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun."},{"issue":"24","key":"2022061013320856100_B2","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and S\u00e9zary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2022061013320856100_B3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022061013320856100_B4","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood."},{"issue":"4","key":"2022061013320856100_B5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med."},{"issue":"1","key":"2022061013320856100_B6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1634\/theoncologist.2010-0306","article-title":"U.S. Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia","volume":"16","author":"Casak","year":"2011","journal-title":"Oncologist."},{"issue":"9759","key":"2022061013320856100_B7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"issue":"17","key":"2022061013320856100_B8","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-10-0570","article-title":"U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab","volume":"16","author":"Lemery","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"15","key":"2022061013320856100_B9","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1158\/1078-0432.CCR-14-0516","article-title":"U.S. Food and Drug Administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2022061013320856100_B10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"2022061013320856100_B11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist."},{"issue":"10214","key":"2022061013320856100_B12","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet."},{"issue":"35","key":"2022061013320856100_B13","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022061013320856100_B14","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood."},{"issue":"7","key":"2022061013320856100_B15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"2022061013320856100_B16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022061013320856100_B17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022061013320856100_B18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med."},{"issue":"8","key":"2022061013320856100_B19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia."},{"issue":"10168","key":"2022061013320856100_B20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"10","key":"2022061013320856100_B21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"9825","key":"2022061013320856100_B22","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet."},{"key":"2022061013320856100_B23","author":"FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients","year":"2020"},{"issue":"2","key":"2022061013320856100_B24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022061013320856100_B25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2022061013320856100_B26","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol."},{"issue":"9747","key":"2022061013320856100_B27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet."},{"issue":"10027","key":"2022061013320856100_B28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet."},{"issue":"8","key":"2022061013320856100_B29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"2022061013320856100_B30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"2022061013320856100_B31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol."},{"issue":"5","key":"2022061013320856100_B32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother."},{"issue":"2","key":"2022061013320856100_B33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022061013320856100_B34","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol."},{"issue":"23","key":"2022061013320856100_B35","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2022061013320856100_B36","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.3324\/haematol.2016.159905","article-title":"Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed\/refractory CD22-positive precursor B-cell acute lymphocytic leukemia","volume":"102","author":"Chevallier","year":"2017","journal-title":"Haematologica."},{"issue":"2","key":"2022061013320856100_B37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol."},{"issue":"4","key":"2022061013320856100_B38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"issue":"18","key":"2022061013320856100_B39","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022061013320856100_B40","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3109\/10428194.2014.986478","article-title":"Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia","volume":"56","author":"Chantepie","year":"2015","journal-title":"Leuk Lymphoma."},{"issue":"10094","key":"2022061013320856100_B41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet."},{"issue":"10","key":"2022061013320856100_B42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J."},{"issue":"7","key":"2022061013320856100_B43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica."},{"issue":"21","key":"2022061013320856100_B44","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2015-01-588392","article-title":"The role of rituximab in adults with warm antibody autoimmune hemolytic anemia","volume":"125","author":"Dierickx","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022061013320856100_B45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica."},{"issue":"7","key":"2022061013320856100_B46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2022061013320856100_B47","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41409-018-0399-7","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","volume":"54","author":"Solomon","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"2022061013320856100_B48","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med."},{"issue":"9","key":"2022061013320856100_B49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol."},{"issue":"19","key":"2022061013320856100_B50","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med."},{"issue":"17","key":"2022061013320856100_B51","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis [published correction appears in Drugs. 2018;78(2):285]","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"2022061013320856100_B52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist."},{"issue":"1","key":"2022061013320856100_B53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med."},{"issue":"7","key":"2022061013320856100_B54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/tri.12100","article-title":"Induction immunosuppression in liver transplantation: a review","volume":"26","author":"Turner","year":"2013","journal-title":"Transpl Int."},{"issue":"8","key":"2022061013320856100_B55","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ajh.25839","article-title":"Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: updated experience from a large-scale study","volume":"95","author":"Liu","year":"2020","journal-title":"Am J Hematol."},{"issue":"4","key":"2022061013320856100_B56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"issue":"6230","key":"2022061013320856100_B57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science."},{"issue":"9","key":"2022061013320856100_B58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"2022061013320856100_B59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol."},{"issue":"9948","key":"2022061013320856100_B60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet."},{"issue":"26","key":"2022061013320856100_B61","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"issue":"6230","key":"2022061013320856100_B62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science."},{"issue":"7793","key":"2022061013320856100_B63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature."},{"issue":"7463","key":"2022061013320856100_B64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258]","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"17","key":"2022061013320856100_B65","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"issue":"38","key":"2022061013320856100_B66","doi-asserted-by":"crossref","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv."},{"issue":"4","key":"2022061013320856100_B67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"21","key":"2022061013320856100_B68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood."},{"issue":"3","key":"2022061013320856100_B69","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies [abstract, published correction appears in","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell."},{"issue":"12","key":"2022061013320856100_B70","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"37","key":"2022061013320856100_B71","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget."},{"key":"2022061013320856100_B72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3004","article-title":"A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms [abstract]","volume":"38","author":"Luke","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022061013320856100_B73","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer."},{"issue":"6","key":"2022061013320856100_B74","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell."},{"issue":"4","key":"2022061013320856100_B75","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res."},{"issue":"5","key":"2022061013320856100_B76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell."},{"issue":"2","key":"2022061013320856100_B77","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell."},{"issue":"8","key":"2022061013320856100_B78","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"27","key":"2022061013320856100_B79","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022061013320856100_B80","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5f9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results [abstract]","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood."},{"issue":"10","key":"2022061013320856100_B81","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med."},{"issue":"11","key":"2022061013320856100_B82","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2022061013320856100_B83","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"2022061013320856100_B84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"17","key":"2022061013320856100_B85","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022061013320856100_B86","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.bbmt.2018.12.129","article-title":"T cell costimulation blockade with CTLA4-Ig (abatacept) for acute Gvhd prevention in HLA matched and mismatched unrelated donor transplantation: results of the first phase 2 trial","volume":"25","author":"Watkins","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022061013320856100_B87","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.3324\/haematol.2019.226696","article-title":"Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients","volume":"105","author":"Tanaka","year":"2020","journal-title":"Haematologica."},{"issue":"1","key":"2022061013320856100_B88","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep."},{"key":"2022061013320856100_B89","first-page":"759","article-title":"The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy","volume-title":"J Immunother.","author":"Tumeh","year":"2010"},{"issue":"8","key":"2022061013320856100_B90","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022061013320856100_B91","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood."},{"issue":"554","key":"2022061013320856100_B92","doi-asserted-by":"crossref","first-page":"eaaz3339","DOI":"10.1126\/scitranslmed.aaz3339","article-title":"The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma","volume":"12","author":"Lulla","year":"2020","journal-title":"Sci Transl Med."},{"issue":"5","key":"2022061013320856100_B93","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jcyt.2019.03.569","article-title":"CD19 chimeric antigen receptor (CAR) engineered epstein-barr virus (EBV) specific T cells\u2014an off-the-shelf, allogeneic CAR T-cell immunotherapy platform","volume":"21","author":"Shen","year":"2019","journal-title":"Cytotherapy."},{"issue":"13","key":"2022061013320856100_B94","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-14-2920","article-title":"CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"357","key":"2022061013320856100_B95","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med."},{"key":"2022061013320856100_B96","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2019-126004","article-title":"Cytokine-induced memory-like (ML) NK cells persist for &gt; 2 months following adoptive transfer into leukemia patients with a MHC-compatible hematopoietic cell transplant (HCT)","volume":"134","author":"Foltz","year":"2019","journal-title":"Blood."},{"issue":"13","key":"2022061013320856100_B97","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"issue":"22","key":"2022061013320856100_B98","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med."},{"issue":"17","key":"2022061013320856100_B99","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv."},{"issue":"6379","key":"2022061013320856100_B100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science."},{"issue":"7","key":"2022061013320856100_B101","doi-asserted-by":"crossref","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One."},{"issue":"3","key":"2022061013320856100_B102","doi-asserted-by":"crossref","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"OncoImmunology."},{"issue":"5769","key":"2022061013320856100_B103","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science."},{"issue":"7395","key":"2022061013320856100_B104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature."},{"issue":"20","key":"2022061013320856100_B105","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-12-0456","article-title":"A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders","volume":"18","author":"Timmerman","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"16","key":"2022061013320856100_B106","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"issue":"11","key":"2022061013320856100_B107","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood."},{"issue":"14","key":"2022061013320856100_B108","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [published correction appears in Blood. 2019;133(24):2625]","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2022061013320856100_B109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"2022061013320856100_B110","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131061","article-title":"Blinatumomab in combination with pembrolizumab is safe for adults with relapsed or refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504 [abstract]","volume":"134","author":"Schwartz","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2022061013320856100_B111","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2022061013320856100_B112","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs."},{"key":"2022061013320856100_B113","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines [abstract]","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood."},{"issue":"26","key":"2022061013320856100_B114","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood."},{"key":"2022061013320856100_B115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.637.637","article-title":"Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart\u00ae protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome [abstract]","volume":"130","author":"Uy","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022061013320856100_B116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol."},{"issue":"36","key":"2022061013320856100_B117","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022061013320856100_B118","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific antibodies in the treatment of hematologic malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"2022061013320856100_B119","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood."},{"issue":"5","key":"2022061013320856100_B120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","article-title":"NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease","volume":"130","author":"Mastaglio","year":"2017","journal-title":"Blood."},{"issue":"5","key":"2022061013320856100_B121","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"26","key":"2022061013320856100_B122","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022061013320856100_B123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"14","key":"2022061013320856100_B124","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"key":"2022061013320856100_B125","author":"FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma","year":"2021"},{"issue":"8","key":"2022061013320856100_B126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"key":"2022061013320856100_B127","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"2022061013320856100_B128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"2022061013320856100_B129","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2022061013320856100_B130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"issue":"20","key":"2022061013320856100_B131","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"key":"2022061013320856100_B132","first-page":"303ra139","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume-title":"Sci Transl Med.","author":"Porter","year":"2015"},{"issue":"5","key":"2022061013320856100_B133","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"issue":"9","key":"2022061013320856100_B134","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol."},{"issue":"10","key":"2022061013320856100_B135","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med."},{"issue":"374","key":"2022061013320856100_B136","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med."},{"issue":"6481","key":"2022061013320856100_B137","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science."},{"issue":"1","key":"2022061013320856100_B138","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep."},{"issue":"4","key":"2022061013320856100_B139","doi-asserted-by":"crossref","first-page":"BSR20200127","DOI":"10.1042\/BSR20200127","article-title":"Gene editing and CRISPR in the clinic: current and future perspectives","volume":"40","author":"Hirakawa","year":"2020","journal-title":"Biosci Rep."},{"key":"2022061013320856100_B140","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia [abstract]","volume":"132","author":"Li","year":"2018","journal-title":"Blood."},{"key":"2022061013320856100_B141","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2017","journal-title":"Mol Ther Oncolytics."},{"issue":"1","key":"2022061013320856100_B142","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep."},{"issue":"48","key":"2022061013320856100_B143","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"issue":"9","key":"2022061013320856100_B144","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"2022061013320856100_B145","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology."},{"issue":"1","key":"2022061013320856100_B146","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation."},{"key":"2022061013320856100_B147","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"2022061013320856100_B148","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"2022061013320856100_B149","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant."},{"issue":"6295","key":"2022061013320856100_B150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"2022061013320856100_B151","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fmicb.2020.01526","article-title":"Impact of vaccines; health, economic and social perspectives","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Front Microbiol."},{"key":"2022061013320856100_B152","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2022061013320856100_B153","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of Bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol."},{"issue":"11","key":"2022061013320856100_B154","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res."},{"key":"2022061013320856100_B155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8016","article-title":"WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM) [abstract]","volume":"35","author":"Koehne","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022061013320856100_B156","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med."},{"issue":"10","key":"2022061013320856100_B157","doi-asserted-by":"crossref","first-page":"e87059","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight."},{"issue":"1","key":"2022061013320856100_B158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J Immunother."},{"issue":"12","key":"2022061013320856100_B159","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022061013320856100_B160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"19","key":"2022061013320856100_B161","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2022061013320856100_B162","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines."},{"issue":"9","key":"2022061013320856100_B163","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs [published correction appears in Nat Rev Drug Discov. 2016;15(9):660]","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2022061013320856100_B164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am J Clin Dermatol."},{"issue":"5448","key":"2022061013320856100_B165","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science."},{"issue":"1","key":"2022061013320856100_B166","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer."},{"issue":"2","key":"2022061013320856100_B167","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ijc.20217","article-title":"Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer","volume":"111","author":"Bauerschmitz","year":"2004","journal-title":"Int J Cancer."},{"issue":"7090","key":"2022061013320856100_B168","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature."},{"issue":"4","key":"2022061013320856100_B169","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J Cell Biochem."},{"issue":"559","key":"2022061013320856100_B170","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med."},{"issue":"1","key":"2022061013320856100_B171","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol."},{"issue":"5","key":"2022061013320856100_B172","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2022061013320856100_B173","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.molmed.2020.04.001","article-title":"The gut microbiota: emerging evidence in autoimmune diseases","volume":"26","author":"Zhang","year":"2020","journal-title":"Trends Mol Med."},{"issue":"6382","key":"2022061013320856100_B174","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science."},{"issue":"6371","key":"2022061013320856100_B175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science."},{"issue":"4","key":"2022061013320856100_B176","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9967","key":"2022061013320856100_B177","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"2022061013320856100_B178","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med."},{"issue":"12","key":"2022061013320856100_B179","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"6","key":"2022061013320856100_B180","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med."},{"issue":"7738","key":"2022061013320856100_B181","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature."},{"key":"2022061013320856100_B182","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129749","article-title":"DC vaccination induces antigen specific immune responses in AML patients: a 1-year interim assessment [abstract]","volume":"134","author":"Eckl","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3709\/1826341\/advancesadv2021004453c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3709\/1826341\/advancesadv2021004453c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:38:10Z","timestamp":1654868290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3709\/477015\/The-promise-and-perils-of-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":182,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004453c","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}